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Bone remodelling: A signalling system for osteoclast regulation
Ellen Filvaroff* and Rik Derynck†
Two physiological regulators of osteoclast maturation
have recently been identified: the secreted protein
osteoprotegerin and the cell-surface ligand to which it
binds. These proteins are likely to play an important
part in the control of bone resorption, but are also likely
to have important roles in other tissues.
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Bone tissue is continuously remodelled through the com-
bined activities of two cell types, osteoblasts and osteo-
clasts. Osteoblasts, which are derived from mesenchymal
cells, deposit bone matrix, whereas osteoclasts, which are
derived from hematopoietic precursor cells, resorb bone
matrix. To maintain a constant bone mass during adult
life, osteoblastic matrix deposition and osteoclastic resorp-
tion must be closely coordinated (reviewed in [1,2]).
Because bone remodeling is continuous, even a slight per-
turbation of this balance can have drastic effects on bone
mass and structure, and result in progressive, metabolic
bone disease. Thus, increased bone resorption relative to
bone deposition causes the gradual bone loss associated
with osteoporosis, whereas decreased bone resorption rela-
tive to bone deposition causes the increased trabecular
bone mass that occurs in osteopetrosis. As a disturbance of
the balance between osteoblastic bone deposition and
osteoclastic bone resorption is responsible for many
skeletal diseases, we need to understand how the activi-
ties of osteoblasts and osteoclasts are regulated and coordi-
nated. Recent studies have identified factors that regulate
osteoclast maturation and control bone resorption.
The important role of osteoblasts in the regulation of
osteoclast maturation is strikingly illustrated by the almost
complete absence of osteoclasts and tissue macrophages in
the osteopetrotic op/op mouse [3]. The consequently
impaired osteoclastic bone resorption and osteopetrosis,
which result from the failure of osteoblasts to produce
active colony stimulating factor-1 (CSF-1) can be rescued
by injection of CSF-1 (reviewed in [4]). CSF-1 thus plays
a critical role in osteoclast development by directly acting
on osteoclasts to control their proliferation and differentia-
tion. CSF-1 may also affect the activity of mature osteo-
clasts, through its ability to induce osteoclast fusion,
survival and chemotaxis (reviewed in [4–6]). The temporal
and spatial pattern of expression of CSF-1 during develop-
ment suggests that it is one of the factors that couples
hematopoiesis to osteogenesis [4].
Various other extracellular factors that regulate osteoclast
maturation and activity have been identified using
osteoblast/stromal cell and osteoclast precursor cell cocul-
ture systems (reviewed in [5–7]). In these cell systems,
osteoclast formation depends on 1,25-dihydroxyvitamin D3
and CSF-1, but it is inhibited by other factors, such as cal-
citonin, interleukin-4 (IL-4), IL-13, and interferon-γ [5,6].
Many of the positive regulatory factors in this system act
primarily on osteoblasts, stimulating osteoclast maturation
indirectly. These factors can be divided into three classes,
according to their signal transduction mechanisms [5,7].
One class, represented by 1,25-dihydroxyvitamin D3, acts
through nuclear receptors of the steroid receptor family. A
second class, including parathyroid hormone (PTH), PTH-
related protein (PTHrP), prostaglandin E2 and IL-1, exerts
its effects by activating protein kinase A. And a third class,
represented by IL-6, IL-11, oncostatin M and leukocyte
inhibitory factor (LIF), stimulates bone resorption through
the receptor-associated gp130 protein [5,7].
In vitro studies led to the proposal that activation of any one
of these three signal transduction pathways would induce
expression of a membrane-associated factor on osteoblasts,
and thus stimulate osteoclast progenitors to differentiate.
This osteoclast stimulatory factor was named osteoclast-dif-
ferentiation factor [5] or stromal-cell-derived osteoclast for-
mation activity [8]. The gene encoding this factor, which is
expressed by activated osteoblast/stromal cells and induces
osteoclast differentiation, has now been cloned [9] and the
protein renamed osteoprotegerin ligand (OPGL). OPGL
and the soluble protein to which it binds, known as osteo-
protegerin (OPG), constitute a ligand–receptor system
which directly regulates osteoclast differentiation and
hence bone density.
From its cDNA sequence, human OPGL is a 317 amino
acid, type II transmembrane protein with a short amino-
terminal intracellular domain and a large carboxy-terminal
extracellular domain [9]. The extracellular region includes
a juxtamembrane segment of 87 amino acids and a
carboxy-terminal domain of 159 amino acids that shows
similarity to the cytokine tumor necrosis factor (TNF) and
related proteins. OPGL is identical to the TNF-related
protein TRANCE/RANKL, the ligand for a member of
the TNF receptor family known as ‘receptor activator 
of NFκB’ (RANK) [10,11], and closely related to the 
apoptosis-inducing, TNF-related ligand TRAIL/Apo-2L
[12,13]. In the developing skeleton, OPGL is expressed
by the mesenchymal cells surrounding the cartilaginous
anlagen and by hypertrophic cartilage, and in areas that
undergo ossification and remodelling, such as in trabecular
bone. OPGL is also made by stimulated osteoblast/stromal
cell lines, which support osteoclastogenesis in vitro, but
not by osteoclasts [9,14]. 
In contrast to most other known cytokines, OPGL stimu-
lates osteoclast differentiation directly, as demonstrated in
an in vitro system where osteoclast differentiation can be
induced in bone marrow or spleen cells by coculture with
osteoblastic/stromal cells. In this system, the stromal cells
provide CSF-1, and stimulation with dexamethasone and
1,25-dihydroxyvitamin D3 induces osteoclast differentia-
tion. Addition of a soluble derivative of OPGL, which con-
tains the TNF-related domain, induces osteoclast
differentiation in the absence of examethasone and 1,25-
dihydroxyvitamin D3. This effect cannot be mimicked by
the closely related cytokine TRAIL [15]. OPGL and CSF-1
together overcome the need for stromal cells to induce
osteoclast maturation [9,14]. These results suggest that
osteoblasts and/or stromal cells provide CSF-1 and OPGL,
and that contact between osteoblast/stromal cells and dif-
ferentiating osteoclasts is required to allow interaction of
transmembrane OPGL on the stromal cell surface with its
receptor on osteoclasts (Figure 1). 
OPGL also stimulates osteoclast activity [9]. CSF-1 alone
allows the generation of small mononuclear cells, which do
not resorb bone, whereas OPGL stimulates development
of active osteoclasts in a CSF-1-dependent manner [9,14].
This synergy of CSF-1 and OPGL may be explained by
the ability of CSF-1 to induce OPGL receptor expression
on osteoclast precursors. Accordingly, CSF-1-treated cul-
tures show a high percentage of cells that directly bind
OPGL. These cells are large and adherent, whereas the
non-binding cells are small and non-adherent [9]. OPGL
also activates resorption by mature osteoclasts in vitro, but
this effect does not depend on CSF-1 [9]. Thus, OPGL
can act at multiple points during osteoclast maturation
(Figure 1). The nature of the OPGL receptor remains
unclear, although, given the identity of OPGL and
RANKL, it may turn out to be RANK.
The importance of OPGL in osteoclast maturation and
bone resorption is underscored by the identification and
characterization of OPG [16,17]. OPG is a secreted,
glycosylated protein of 401 amino acids, which naturally
forms a disulfide-bonded dimer of 110 kDa. The sequence
of OPG shows strong similarity to TNF receptor super-
family members in the amino-terminal half, and similarity
to TNF receptor ‘death domains’ in two carboxy-terminal
segments. OPG lacks a transmembrane region, however,
and has been found only in secreted form. OPG is made
by a variety of tissues, but is expressed at high levels in
cartilaginous primordia of developing bones, consistent
with a role in skeletogenesis [16]. OPG inhibits osteoclas-
tic differentiation in the coculture system, presumably as a
result of its ability to bind and neutralize OPGL produced
by the activated stromal cells [14,17] (Figure 1). OPG pro-
duction by osteoblast/stromal cells is inhibited by 1,25-
dihydroxyvitamin D3 [17], reinforcing the osteoclastic
differentiation caused by concomitant induction of OPGL
production by osteoblasts [17]. OPGL is not the only
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Figure 1
Proposed roles for CSF-1, OPGL and OPG in
the regulation of osteoclast maturation by
osteoblasts. (See text for details.)
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ligand for OPG, however, as OPG also binds TRAIL with
high affinity and blocks TRAIL-induced apoptosis, just as
TRAIL blocks OPG-induced inhibition of osteoclastogen-
esis in vitro [15]. OPG is therefore not merely an inhibitor
of osteoclast maturation and activity.
That OPG acts as an inhibitor of osteoclast differentiation
is also apparent from the phenotype of OPG-overexpress-
ing transgenic mice. These mice show an increase in tra-
becular bone density, caused by the decreased bone
resorption that results from their relatively low numbers of
mature osteoclasts [16]. Unlike other osteopetrotic mouse
models, these transgenic mice do not have defects in the
relative size or shape of their bones, nor abnormalities in
tooth eruption. This difference may reflect OPG’s role in
regulating the terminal stages of osteoclast differentiation,
consistent with the normal numbers of osteoclast precur-
sors in these mice [16]. In some other osteopetrotic mouse
models, such as mice deficient in CSF-1 or NF-κB1 and
NF-κB2, osteoclast differentiation is affected at earlier
stages (reviewed in [18]). These mutations not only lead to
decreased numbers of osteoclasts, but can also influence
other cell types derived from hematopoietic or myeloid
progenitors, such as monocytes and macrophages [4,18]. In
other osteopetrotic mouse mutants, such as microphthalmia
or c-Src-deficient mice, the number of osteoclasts is
normal but their activity is impaired, presumably because
of an intrinsic osteoclast defect [18]. Thus, unlike the
defects in other osteopetrotic mice, OPG overexpression
induces osteopetrosis by interfering with the ability of
osteoblasts to directly stimulate osteoclast differentiation.
Further evidence that OPG is a physiological regulator of
bone mass comes from the observation that OPG-deficient
mice exhibit severe bone porosity and a high incidence of
fractures [19], reminiscent of human osteoporosis [20].
The bone porosity in OPG-deficient mice is more severe
than in other animal models of osteoporosis, consistent
with the direct and potent effect of OPG on osteoclast dif-
ferentiation. Previous studies have shown that inactivation
or overexpression of genes for other secreted regulators of
osteoclastic resorption can result in osteoporosis. For
example, overexpression of IL-4 [21], G-CSF [22] or
TGF-β2 [23] result in osteoporotic phenotypes, albeit
with different etiologies.
The increased bone resorption in OPG-deficient mice is
associated with an increase in osteoclast surface as a propor-
tion of total bone surface [19]. Injection of OPGL into
normal mice similarly results in reduced bone volume, but
without a change in osteoclast number; rather, the increase
in osteoclast activity is accompanied by an increase in size
and nuclearity of osteoclasts. This stimulation of osteoclast
development and activity by OPGL in vivo is consistent
with the finding that OPGL binds to both bone marrow
osteoclast progenitors and osteoclasts [9]. OPG-deficient
mice also exhibit an increase in osteoblast surface and
higher osteocyte density [19]. These changes are probably
caused by the increased osteoclast activity, as bone forma-
tion is normally coupled to bone resorption [1,2]. This cou-
pling could be effected by the release of stored growth
factors (such as TGF-β) during osteoclastic bone matrix
resorption, which would then alter osteoblast differentia-
tion and activity. Osteopetrotic animals similarly show
changes in osteoblast function [18]. The current in vitro and
in vivo results thus strongly suggest that OPG is a physio-
logical inhibitor of osteoclast differentiation, which plays a
role in maintaining the normal balance between osteoblas-
tic bone deposition and osteoclastic bone resorption.
OPG is produced by many tissues other than bone, includ-
ing the intestine, heart, kidney, lung and placenta, and
hematopoietic and immune organs [16]. OPG’s function in
these tissues remains to be determined, but is most likely
not restricted to OPGL neutralization. For example, OPG
can inhibit TRAIL-induced apoptosis in vitro [15], which
may account for the enlarged spleens in OPG-overex-
pressing mice [16]. OPG may also be involved in in regu-
lating calcium and phosphate transport and homeostasis,
given its expression in the intestine, kidney and bone
[2,16]. OPG is also likely to be a physiological suppressor
of local calcification in blood vessels, as OPG-deficient
mice show calcification of the aorta and renal arteries [19].
This mechanistic connection between bone and blood
vessel pathology is consistent with the presence of several
bone matrix proteins and minerals in calcified arteries
[19], and the association between vascular calcification
and osteoporosis in humans [20].
OPGL is also expressed outside the skeleton — high
levels occur in lymph nodes, and lower levels in the
thymus, spleen, peripheral blood leukocytes, bone
marrow, heart, placenta, skeletal muscle, stomach and
thyroid gland [9–11]. The OPGL receptor RANK, in con-
trast, is ubiquitously expressed, with highest levels in
thymus, skeletal muscle, liver, colon, small intestine and
adrenal gland [10]. These observations suggest that RANK
may have several ligands and that OPGL plays a role in
cell types other than osteoclasts. In vitro results indeed
suggest a role for OPGL in T-cell activation and viability,
perhaps through its ability to activate NF-κB [10]. OPGL
also increases survival of dendritic cells in vitro and
enhances their ability to stimulate naive T cells in a mixed
lymphocyte reaction [10,24]. OPGL may therefore help to
coordinate the activity of dendritic and T cells [10,11,24].
The seeming similarity between the activities of OPGL in
bone and in the immune system is perhaps surprising. In
vitro, activation of T cells leads to a rapid induction of
OPGL production, which then enhances dendritic cell sur-
vival, presumably via the RANK receptor. The survival and
activation of antigen-specific T cells and antigen-presenting
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dendritic cells may perhaps be closely linked in this way.
This linkage may resemble the coordination of osteoblast
and osteoclast activities: OPGL expression is induced fol-
lowing activation of stromal osteoblasts and stimulates
osteoclast differentiation. Whereas the OPGL-producing
cells in these two systems are of different origin, dendritic
cells and osteoclasts are both hematopoietic cell types of
the monocyte–macrophage lineage. The transcription
factor NF-κB, implicated in the T-cell response to OPGL,
may also have a role in OPGL-induced signalling during
osteoclast development: mice deficient for NF-κB1 and
NF-κB2 develop osteopetrosis because of a defect in
osteoclast differentiation [25]. A further characterization of
the activities of the OPG/OPGL/RANK system in vitro
and in vivo should help elucidate these possible analogies
between bone cell biology and immunology.
The similarity between OPGL and TRAIL and the ability
of OPG to neutralize TRAIL [15] suggest that OPG may
be a physiological inhibitor of apoptosis in several contexts,
including hematopoietic and lymphoid organs. Further-
more, the likelihood that OPGL acts via RANK, which is
related to receptors that are known to induce apoptosis, also
suggests a close relationship between osteoclast differentia-
tion and the apoptotic response. Whether RANK activation
induces or inhibits apoptosis of osteoclasts or their progeni-
tors remains to be determined. Clearly, the possibility that
the OPG/OPGL regulates both differentiation and apopto-
sis in bone and other organs is interesting and needs to be
investigated further if these molecules are to be considered
for therapeutic treatment of metabolic bone disorders.
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